k8¿­·¢(Öйú)

ÕâÊÇÃèÊöÐÅÏ¢

ÐÂÎÅ×ÊѶ

ÐÂÎÅ×ÊѶ
ÁôÑÔ×Éѯ
Óë×îÐÂÏûÏ¢±£´æͬ²½
/
/
Cell·¢ÎĽÒʾйڷÎÑײ¡È˵ÄѪҺµ°°××éÌØÕ÷

Cell·¢ÎĽÒʾйڷÎÑײ¡È˵ÄѪҺµ°°××éÌØÕ÷

  • ·ÖÀࣺ»ªÓ¯ÊÓ½Ç
  • ×÷ÕߣºÈðÈð
  • À´Ô´£ºk8¿­·¢(Öйú)¹«ÖÚºÅ

¡¾¸ÅÒªÃèÊö¡¿ÔõÑù²ÅÄÜÈ«ÃæµÄ¶ÔѪҺµ°°××é½øÐмì²â£¬É¸Ñ¡ÖØÒªµÄDZÔÚ±êÖ¾ÎïÄØ£¿½ñÌìk8¿­·¢(Öйú)¾ÍÒÔ½üÆÚ·¢±íµÄһƪÏà¹ØÎÄÕÂΪÀý£¬·ÖÏíѪҺµ°°×±êÖ¾ÎïµÄÓÅÑ¡½â¾ö·½°¸£¬ÒÔ÷϶ÁÕߣ¡

Cell·¢ÎĽÒʾйڷÎÑײ¡È˵ÄѪҺµ°°××éÌØÕ÷

¡¾¸ÅÒªÃèÊö¡¿ÔõÑù²ÅÄÜÈ«ÃæµÄ¶ÔѪҺµ°°××é½øÐмì²â£¬É¸Ñ¡ÖØÒªµÄDZÔÚ±êÖ¾ÎïÄØ£¿½ñÌìk8¿­·¢(Öйú)¾ÍÒÔ½üÆÚ·¢±íµÄһƪÏà¹ØÎÄÕÂΪÀý£¬·ÖÏíѪҺµ°°×±êÖ¾ÎïµÄÓÅÑ¡½â¾ö·½°¸£¬ÒÔ÷϶ÁÕߣ¡

  • ·ÖÀࣺ»ªÓ¯ÊÓ½Ç
  • ×÷ÕߣºÈðÈð
  • À´Ô´£ºk8¿­·¢(Öйú)¹«ÖÚºÅ
  • ·¢²¼Ê±¼ä£º2022-03-16 10:11
  • ·ÃÎÊÁ¿£º
ÏêÇé

Ѫ½¬µ°°×µÄŨ¶È¿ç¶È·¶Î§¼°Æä¹ã£¬´Ó¸ß·á¶È°×µ°°×¡¢ÃâÒßÇòµ°°×µÈµÄmg/ml£¬µ½°×½éËØ¡¢¸ÉÈÅËصÈϸ°ûÒò×ÓµÄpg/ml£¬ºÜÄÑÓõ¥Ò»µÄ¼¼Êõ¿ÉÒÔ½«ÕâЩµ°°×¶¼ÄÜͬʱ¼ì²âµ½£¬ÌرðÊÇ¿¼Âǵ½µÍ·á¶Èµ°°×µÄ¼ø¶¨ºÍ¼ì²â£¨Í¼1£©¡£

ÔõÑù²ÅÄÜÈ«ÃæµÄ¶ÔѪҺµ°°××é½øÐмì²â£¬É¸Ñ¡ÖØÒªµÄDZÔÚ±êÖ¾ÎïÄØ£¿½ñÌìk8¿­·¢(Öйú)¾ÍÒÔ½üÆÚ·¢±íµÄһƪÏà¹ØÎÄÕÂΪÀý£¬·ÖÏíѪҺµ°°×±êÖ¾ÎïµÄÓÅÑ¡½â¾ö·½°¸£¬ÒÔ÷϶ÁÕߣ¡

 

ͼ1 Ñª½¬µ°°×Ũ¶È·¶Î§(Schiess et al. Mol Oncol. 2009)

½üÆÚCellÔÓÖ¾·¢±íÁËÒ»ÏîÌâΪ“A blood atlas of COVID-19 defines hallmarks of disease severity and specificity”µÄÑо¿1£¬¸ÃÑо¿ÀûÓöà×éѧ¼¼ÊõÚ¹ÊÍÁËCOVID-19µÄÍâÖÜѪÌØÕ÷¡£¸ÃÑо¿ÄÉÈëÁË100¶àÃûסԺµÄCOVID-19»¼Õߣ¬ÒÔ¼°¿µ¸´ÆÚµÄÉçÇøCOVID-19²¡ÈË£¬½¡¿µÕߣ¬ÖØÖ¢µÄÁ÷¸Ð»¼ÕߺÍŧ¶¾Ö¢»¼Õß¡£ÆäÖÐסԺµÄCOVID-19²¡ÈËÒÀ¾ÝWHOµÄ·ÖÀà±ê×¼·ÖΪÁËÖжÈ¡¢ÖضÈ¡¢Î£ÖضÈÈý¸ö³Ì¶È¡£Ñо¿ÕßÀûÓÃÖÊÆ×Á÷ʽ£¨CyTOF£©¡¢CITE²âÐò¡¢×ªÂ¼×é²âÐò¡¢µ¥Ï¸°û²âÐò¡¢BCRºÍTCR²âÐò¡¢4Dµ°°××éTimsTOFÖÊÆ×¼¼ÊõºÍLuminexϸ°ûÒò×Ó¼ì²â¼¼Êõ·ÖÎöÁËCOVID-19²¡ÈËÍâÖÜѪÌØÓеÄϸ°û×é³ÉºÍ·Ö×ÓÌØÕ÷£¬Í¨¹ýWGCNA·ÖÎö¡¢»úÆ÷ѧϰ½øÐÐÌØÕ÷±äÁ¿Ñ¡ÔñµÈËã·¨ÒÔ¼°¶à×éѧÕûºÏ·ÖÎö·½·¨¼ø¶¨ÁËÓëCOVID-19¼²²¡ÑÏÖس̶ÈÃÜÇÐÏà¹ØµÄÃâÒßϸ°ûÑÇȺ¡¢¹Ø¼üµÄ»ùÒòºÍµ°°×ÒÔ¼°ÖØÒªµÄÉúÎïѧ¹ý³ÌºÍͨ·£¬ÎªCOVID-19¼²²¡µÄ¾«×¼ÖÎÁÆÌṩÁËÖØÒªµÄ²Î¿¼ÒÀ¾Ý£¨Í¼2£©¡£

 

ͼ2 COVID-19¼²²¡µÄѪҺ¶à×éѧÑо¿

 

ÕâÏîÑо¿ÀûÓÃÁËÖÊÆ×¼¼ÊõºÍ¿¹ÌåоƬ¼¼Êõ¿ªÕ¹ÑªÇå/½¬µ°°××éѧµÄ·ÖÎö¡£Ñо¿ÕßÊ×ÏÈͨ¹ý4Dµ°°××éƽ̨TimsTOF ProÖÊÆ×ÒÇ (Bruker Daltonics)·ÖÎöÁËÀ´×Ô257¸öÊÜÊÔÕß×ܹ²340·ÝѪ½¬Ñù±¾¡£ÖÊÆ×½á¹û±íÃ÷Ѫ½¬µ°°××é¿ÉÒÔÒÀ¾Ý¼²²¡µÄÑÏÖس̶Ƚ«Ñù±¾·Ö¿ª£¨Í¼3A£©£¬¼²²¡µÄÑÏÖØÐÔÓë¼±Ïà·´Ó¦µ°°×¡¢²¹Ìåϵͳµ°°×ÃÜÇÐÏà¹Ø£¬ÀýÈçSAA1, SAA2, CRP, C5, C6, C9, CFB, SERPINA3, SERPINA1, ITIH3, APCµÈµ°°×£¨Í¼3B£©¡£µ°°×»¥×÷ÍøÂç·ÖÎöչʾÁ˲ÎÓ뵨¹Ì´¼×ªÔË£¨cholesterol transport£©ºÍ ÏËάµ°°×ѪÄý(fibrin blood clots)µÄ³ÉÔ±·Ö±ðÐγÉÁË2¸ö×î´óµÄµ°°×´Ø£¨Í¼3C£©¡£ËµÃ÷ÁËÕâЩÉúÎïѧ¹ý³ÌÓëCOVID-19¼²²¡µÄÑÏÖس̶ȷdz£Ïà¹Ø¡£Ö®ºóÑо¿ÕßÀûÓÃLuminex¼¼Êõ¼ì²âÁËѪÇå/½¬ÖÐ51¸öϸ°ûÒò×ÓºÍÇ÷»¯Òò×Ó¡£½á¹û±íÃ÷ÁË25¸öÒò×ÓÔÚCOVID-19²¡È˺ͽ¡¿µÈ˼ä´æÔÚÏÔÖøÐÔ²îÒ죬ÆäÖÐCCL2, CCL19, CCL20, CXCL10, GM-CSF, IL-6, IL-8, IL-15, S100A9, SCGFÓëסԺCOVID-19²¡È˵ÄÑÏÖس̶ȸ߶ÈÏà¹Ø£¨Í¼3D£©¡£½øÒ»²½µÄµ°°×ºÍÁÙ´²Ö¸±êÏà¹ØÐÔÍøÂç·ÖÎöչʾÁ˼¸¸öÁÙ´²ÌØÕ÷ÓëÍøÂçÖÐÐĵĽڵ㵰°×³ÊÏÖºÜÇ¿µÄÏà¹ØÐÔ£¬°üÀ¨GM-CSF, CXCL10, TREM-1, CCL2/19, TF, IL-6/15, MPO, S100A9µ°°×£¨Í¼3E£©¡£

 

ͼ3 4DÖÊÆ׺ÍоƬ¼¼Êõ·ÖÎöѪ½¬µ°°××é

Ñо¿ÕßÓÖÀûÓÃÏàËÆÍøÂçÈںϵķ½·¨£¨Similarity Network Fusion, SNF£©ÕûºÏÖÊÆ×Êý¾ÝºÍоƬÊý¾Ý¶ÔסԺCOVID-19²¡È˽øÐÐÑÇÐÍ·ÖÀࣨͼ4A£©¡£½á¹ûºÜÃ÷ÏÔ¿ÉÒÔ½«²¡ÈË·ÖΪÁ½¸öÑÇȺ£¬²¢ÇÒÕâÁ½¸öÑÇȺҲ¿ÉÒÔͨ¹ýÁÙ´²Ö¸±êÇø·Ö£¨Í¼4B£©£¬ÀýÈçÎüÑõŨ¶ÈºÍSOFA·ÖÊý£¬ÑÇȺ1¼²²¡ÑÏÖس̶ȵÍ£¬ÑÇȺ2¼²²¡ÑÏÖس̶ȸߣ¨Í¼4C£©¡£Óë֮һֵģ¬ÕâÁ½¸öÑÇȺµÄ²¡ÈËÓë28ÌìËÀÍöÂÊÃÜÇÐÏà¹Ø£¬ÑÇȺ1Óе͵ÄËÀÍöÂÊ£¬¶øÑÇȺ2ÓиßËÀÍöÂÊ£¨Í¼4D£©¡£ÕâЩ½á¹û˵Ã÷ÁËѪÇå/½¬µ°°××é¿ÉÒÔ×÷ΪCOVID-19²¡ÈËÔ¤ºóµÄ±êÖ¾Îï¡£×îºóÑо¿Õß¼ø±ðÁËÇø·ÖÁ½¸öÑÇȺ×îÖ÷ÒªµÄ11¸öµ°°×£¬°üÀ¨IL-6, IL-8, CCL2, CCL19, CCL20, CXCL10, S100A9, SAA1, SERPINA3, GM-CSF, CLEC11A¡£

k8¿­·¢(Öйú)½«ÖÊÆ×¼¼ÊõºÍ¿¹ÌåоƬ¼¼ÊõÓлú×éºÏ£¬ÊµÏÖѪҺ±êÖ¾ÎïµÄÈ«·½Î»µÄ¼ì²â£¡

 

ͼ4 »ùÓÚѪ½¬µ°°××éµÄ¼²²¡·ÖÐÍ

 Ñо¿ÕßÓÖ½øÐÐÁ˶à×éѧµÄÕûºÏ·ÖÎö£¬Í¨¹ý»úÆ÷ѧϰËã·¨¼ø¶¨ÁËÔ¤²â¼²²¡ÑÏÖس̶ȵÄDZÔÚ±êÖ¾Î·¢ÏÖÁ˾ßÓиßЧÄܵÄÔ¤²â±êÖ¾Îï×éºÏ£¬°üÀ¨SAA2, CRP, IGHG4, CL20, CCL2, IL-6ºÍC5aµ°°×£¨Í¼5A,B£©¡£Ñо¿Õß×îºóÀûÓÃÕóÁÐÏ¡Êè·Ö½â£¨SDA£©Ëã·¨·¢ÏÖÁ˺ܶàÓë¼²²¡ÑÏÖس̶ÈÏà¹ØµÄÄ£¿é£¬ÕâЩÄ£¿éÓɲ»Í¬µÄϸ°ûÑÇȺ¡¢»ùÒòºÍµ°°××é³É£¨Í¼5C£©¡£ÀýÈçÆäÖÐÒ»¸öÓëCOVID-19¼²²¡ÑÏÖس̶È×îÏà¹ØÄ£¿ì×é³É°üÀ¨Ôö¼ÓµÄѪ½¬Ç÷»¯Òò×ÓCXCL8, CXCL10, CCL20ºÍGM-CSF£¬¼°¼±Ïà·´Ó¦µ°°×SAA1/2, SERPINA3, LRG1 ºÍLBP; ¼õÉÙµÄÖм䵥ºËϸ°û; ¸ß±í´ïµÄ·Ö×Ó°éÂÂCLU»ùÒòºÍ¼×»ùתÒÆøMETTL7B»ùÒò£»Ïµ÷µÄlgEÊÜÌå»ùÒòºÍ¶à¸öHLA-II»ùÒò£»Ó뿹ԭ³ÊµÝ¡¢TCRÐźźÍÏø´­Ïà¹ØµÄ¸»¼¯Í¨Â·µÈ£¨Í¼5D£©¡£×îºó»¹¼ø±ðÁËÏà¶ÔÓÚŧ¶¾Ö¢ºÍÁ÷¸Ð¼²²¡£¬COVID-19Ïà¹ØµÄһЩÌØÓеÄÄ£¿é£¬×ÜÖ®ÕâЩ½á¹û˵Ã÷ÁËͨ¹ýµ°°××顢ת¼×é¡¢µ¥Ï¸°ûµÈ¶à×éѧ·ÖÎö¿ÉÒÔ¼ø¶¨COVID-19¼²²¡ÑÏÖس̶ȺÍÌØÒìµÄÏà¹ØѪҺÌØÕ÷£¬ÎªÀí½âCOVID-19¼²²¡µÄ²¡Àí»úÖÆ£¬¼ø¶¨Õï¶ÏºÍÔ¤²â±êÖ¾Îï¼°¾«×¼ÖÎÁÆÌṩÖØÒªÒÀ¾Ý¡£

 

|   ×ܽáÓë½áÂÛ

Ä¿Ç°³£ÓõÄÁ½ÖÖѪ½¬µ°°×¼ì²â¼¼ÊõÊÇÖÊÆ×¼¼ÊõºÍ»ùÓÚ¿¹ÌåµÄ¼ì²â¼¼Êõ¡£¶ÔÓÚÖÊÆ×¼¼Êõ£¬Ñª½¬¸ß·á¶Èµ°°×»áÑڸǺ͸ÉÈŵͷá¶Èµ°°×µÄ¹Û²ì¡£µ«ÊǶàÖÖÑù±¾Ô¤´¦Àí·½·¨µÄÓ¦Óü°ÖÊÆ×¼¼ÊõµÄÉý¼¶¿ÉÒÔÔÚÒ»¶¨³Ì¶ÈÉϽâ¾öÉÏÊöÎÊÌâ¡£ÀýÈçÖÊÆ×¼ì²âÇ°Ô¤ÏÈÈ¥³ýѪ½¬10¶àÖָ߷á¶Èµ°°×£¬²ÉÓÃÊý¾Ý·ÇÒÀÀµµÄ²É¼¯Ä£Ê½£¨DIA£©ÊµÏÖëĶÎÈ«·¶Î§µÄɨÃ裬ÌرðÊÇ°éËæ×Å4Dµ°°××éʱ´úµÄµ½À´£¬ÖÊÆ׵ļì²âÁéÃô¶È¡¢×¼È·¶ÈºÍ¸²¸ÇÉî¶ÈµÃµ½ÁË¿çʱ´úµÄÌáÉý¡£ÕâЩ¸ß¾«¶ÈµÄÖÊÆ×¼¼ÊõÒѾ­Öð½¥³ÉΪѪ½¬±êÖ¾Îï·¢Ïֺͼø¶¨µÄÖØÒªÊֶΡ£»ùÓÚ¿¹ÌåµÄ¼ì²â¼¼Êõ°üÀ¨¸÷ÖÖ¹ÌÏ࿹ÌåоƬ¼°LuminexÒºÏàÐü¸¡Ð¾Æ¬µÈ£¬ÕâЩоƬÒÀÀµÓÚʹÓõĿ¹Ì壬¿ÉÒÔ¼ì²âÄÇЩµÍ·á¶ÈµÄµ°°×£¬¶øÎÞÐèÈ¥³ý¸ß·á¶Èµ°°×£¬ÌرðÊÊÓÃÓÚ¼ì²âѪҺÖк¬Á¿Ïà¶ÔµÍµÄÑ×Ö¢Òò×Ó¡¢Éú³¤Òò×Ó¡¢Ç÷»¯Òò×ÓºÍÉñ¾­Òò×ӵȡ£ÖÊÆ׺Ϳ¹ÌåоƬÁ½ÖÖ¼¼Êõ¿ÉÒÔÓÅÊÆ»¥²¹£¬Á½Õß½áºÏÎÞÒÉ¿ÉÒԷḻ¼ø¶¨µÄµ°°×ÊýÁ¿£¬·¢ÏÖ¸ü¶àDZÔڵıêÖ¾Îï¡£

k8¿­·¢(Öйú)Ò»Ö±ÖÂÁ¦ÓÚѪҺµ°°×±êÖ¾ÎïµÄÑо¿ºÍ·þÎñ£¬Æ¾½è¶àÄê¾­Ñé¼°ÏȽøµÄ¼ì²âƽ̨¿ÉÒÔΪ´ó¼ÒÌṩϵͳ»¯µÄѪҺ±êÖ¾Îï½â¾ö·½°¸¡£¾Íµ°°××é¶øÑÔ£¬³ýÁ˳£¹æµÄ¼¼Êõ£¬»ªÓ¯»¹ÓµÓÐÄ¿Ç°×îÏȽøµÄ4D-DIAÖÊÆ×¼ì²âƽ̨£¬²¢ÇÒÊÇ4Dµ°°××é“˫ƽ̨”£¬¿ÉÂú×㲻ͬÑо¿µÄÐèÇ󡣶ÔÓÚѪҺµÍ·á¶ÈµÄϸ°ûÒò×Ó£¬»ªÓ¯ÓµÓГ¸ßͨÁ¿¿¹ÌåоƬ”¡¢“LuminexÒºÏàÐü¸¡Ð¾Æ¬”¡¢“µ¥·Ö×Ó¸ßÃôSimoa¼¼Êõ”Èý¸öϸ°ûÒò×Ó¼ì²âƽ̨£¬¿ÉÒÔͬ²½¼ì²â¼¸Ê®ÖÁ¼¸Ç§¸öÒò×Ó£¬¼ì²âÁéÃô¶È¿ÉÒÔ´ïµ½fg¼¶£¨Simoa£©¡£

k8¿­·¢(Öйú)½«ÖÊÆ×¼¼ÊõºÍ¿¹ÌåоƬ¼¼ÊõÓлú×éºÏ£¬ÊµÏÖѪҺ±êÖ¾ÎïµÄÈ«·½Î»µÄ¼ì²â£¡

|   ²Î¿¼ÎÄÏ×

1.COvid-19 Multi-omics Blood ATlas (COMBAT) Consortium. A blood atlas of COVID-19 defines hallmarks of disease severity and specificity. 2022. In Press.

k8¿­·¢(Öйú)

µØÖ·£ºÉϺ£ÊÐãÉÐÐÇøÂÌÖÞ»·Â·396Ū5´±4²ã

µç»°£º400-869-2936£¬021-33968791

ÓÊÏ䣺support@wayenbiotech.com

´«Õ棺021-33938792

QQ£º2120485725

Õ½ÂÔºÏ×÷

Õ½ÂÔºÏ×÷

·¢²¼Ê±¼ä£º2021-08-11 17:21:10

|    Full Moon    |    RayBiotech    |    CDI    |    IZON    |    Bio-Rad    |    R&D Systems    |    IsoPlexis    |    ÄÏÄ£ÉúÎï    |    Å·Ò×ÉúÎï    |    ÆäÃ÷ÐÅÏ¢    |    ÃÀ¼ªÉúÎï    |    ÂóÌØ»æÆ×    | 

 

Ìرð˵Ã÷£º±¾ÍøËùÓÐÍøÒ³¾ùΪk8¿­·¢(Öйú)Ô­´´ÐÅÏ¢£¬×ªÔرØÐëÕ÷Çók8¿­·¢(Öйú)ͬÒ⣬²¢Í¬Ê±×¢Ã÷±¾ÍøÃû³Æ¼°ÍøÖ·¡£

רÀû´úÂë

·¢²¼Ê±¼ä£º2023-06-09 17:38:30
Copyright @ 2021 ÉϺ£k8¿­·¢(Öйú)Ò½Ò©¿Æ¼¼ÓÐÏÞ¹«Ë¾ °æȨËùÓÐ
Record »¦ICP±¸2022031428ºÅ-1
ÍøÕ¾½¨É裺ÖÐÆó¶¯Á¦ ÉϺ£
ËÑË÷
ËÑË÷
¹Ø±Õ
¿Í»§ÁôÑÔ
ÑéÖ¤Âë